

ENDOCYTE INC  
Form 8-K  
June 01, 2012

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 31, 2012

Endocyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction  
of incorporation)

001-35050

(Commission  
File Number)

35-1969-140

(I.R.S. Employer  
Identification No.)

3000 Kent Avenue, Suite A1-100, West  
Lafayette, Indiana

(Address of principal executive offices)

47906

(Zip Code)

Registrant's telephone number, including area code:

765-463-7175

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Top of the Form**ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

Endocyte, Inc. (the Company) held its annual meeting of stockholders on May 31, 2012. Stockholders took the following actions:

elected three (3) directors for three-year terms ending at the 2015 annual meeting of stockholders (Proposal 1); and

ratified the Audit Committee's appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2012 (Proposal 2).

The vote tabulation for each proposal follows:

Proposal 1 Election of Directors

Nominee	For	Withhold	Broker Non-Votes
Keith E. Brauer	20,542,873	172,117	6,937,742
Ann F. Hanham, PhD.	20,529,772	185,218	6,937,742
Peter D. Meldrum	20,331,793	383,197	6,937,742

Proposal 2 Ratification of Independent Registered Public Accounting Firm

For	Against	Abstained	Broker Non-Votes
27,637,328	15,384	20	0

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

*June 1, 2012*

By: */s/ Michael A. Sherman*

---

*Name: Michael A. Sherman  
Title: Chief Financial Officer*